Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 ...

BD (Becton, Dickinson and Company) recently expanded its European infectious disease diagnostics portfolio after IVDR ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Waters has agreed to combine with BD’s biosciences and ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

BD (Becton, Dickinson and Company) has agreed to combine its biosciences and diagnostic solutions business with Waters Corporation, creating a new life science and diagnostics company. The agreement ...

Waters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, ...

Investing.com -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has announced that its board of directors has unanimously authorized a plan to separate BD's ...

The BD Accuri™ C6 is a personal flow cytometer that brings flow cytometry within reach by being easy to use, simple to maintain, and affordable. The analytical power and versatility of today’s ...

At BD Life Sciences–Biosciences (BDB), we take pride in our history. Since the innovation of our technology in the 1970s where Dr. Leonard Herzenberg of Stanford invented the fluorescence-activated ...

On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares.

"New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and ...